Aimovig (erenumab) has been a meaningful treatment option for many migraine sufferers, with real patients reporting a range of outcomes from dramatic reductions in monthly migraine days to more modest improvements or, in some cases, difficult side effects that led them to stop treatment. The injectable medication, which targets the calcitonin gene-related peptide (CGRP) receptor, was the first in its class approved by the FDA back in 2018, and since then thousands of patients have shared their experiences through online communities, clinical follow-ups, and patient advocacy forums. One recurring theme is that results vary considerably from person to person — some patients describe going from fifteen or more migraine days per month down to just a handful, while others notice little change after several months of injections.
This article draws on the types of experiences patients have commonly reported, the clinical evidence behind Aimovig, and the practical realities of using a self-injected biologic for chronic or episodic migraine. We will cover how Aimovig works in the brain, what realistic expectations look like based on trial data, the side effects patients most frequently mention, how the drug compares to other CGRP-targeting treatments, cost and access barriers, and what the treatment means specifically for patients who also face cognitive or neurological concerns. If you or someone you care for lives with both migraine disease and concerns about long-term brain health, understanding this treatment in full context matters.
Table of Contents
- What Results Are Aimovig Patients Actually Reporting for Migraine Relief?
- How Does Aimovig Work Differently Than Traditional Migraine Preventives?
- What Side Effects Do Patients Most Commonly Report With Aimovig?
- How Does Aimovig Compare to Other CGRP Treatments for Migraines?
- What Are the Cost and Access Barriers for Aimovig Injections?
- What Should Dementia Caregivers Know About Aimovig and Brain Health?
- Where Is Aimovig Headed and What Are Patients Watching For?
- Conclusion
- Frequently Asked Questions
What Results Are Aimovig Patients Actually Reporting for Migraine Relief?
Patient-reported outcomes with Aimovig tend to cluster into a few categories. In clinical trials that supported the drug’s approval, patients with episodic migraine experienced an average reduction of roughly one to two migraine days per month compared to placebo, and those with chronic migraine saw somewhat larger absolute reductions. However, averages can be misleading. A subset of patients — often called “super responders” — report reductions of fifty percent or more in their monthly migraine days, which for someone suffering fifteen-plus days a month can feel life-changing. On the other end, a meaningful portion of patients report minimal benefit even after three to six months of consistent use, which is the timeframe most neurologists suggest before concluding the medication is not working.
In online patient communities and published survey data, many users describe a pattern where the first month brings modest improvement, the second month is more noticeable, and by months three or four the full effect becomes apparent. Others describe an initial honeymoon period followed by a return of more frequent migraines. One common account involves a patient who had tried multiple preventive medications — topiramate, propranolol, amitriptyline — with either inadequate relief or intolerable side effects, and found that Aimovig finally gave them enough reduction in migraine frequency to return to work or resume daily activities. But it is important to set expectations honestly: not everyone has that experience, and the medication is not a cure. Most patients who respond well still have migraines, just fewer of them. A limitation worth noting is that clinical trials primarily measured migraine day reduction, which does not fully capture what patients care about — intensity of remaining attacks, associated symptoms like nausea or light sensitivity, and overall quality of life are harder to quantify but matter enormously. Some patients report that even when their migraine count does not drop dramatically, the attacks they do have are less severe, while others say the frequency drops but individual episodes remain just as debilitating.
How Does Aimovig Work Differently Than Traditional Migraine Preventives?
Aimovig is a monoclonal antibody that blocks the CGRP receptor, which is a fundamentally different mechanism than older migraine preventives. Traditional options like beta-blockers, anticonvulsants, and tricyclic antidepressants were all developed for other conditions and happened to show some benefit for migraine prevention as a secondary finding. They work broadly on the nervous system and come with side effect profiles that reflect their original purposes — cognitive dulling from topiramate, weight gain from amitriptyline, fatigue from propranolol. Aimovig, by contrast, was designed specifically for migraine and targets a pathway directly implicated in migraine pathophysiology. this specificity is a double-edged sword.
On one hand, the targeted mechanism means fewer systemic side effects for most patients. People generally do not report the brain fog or cognitive slowing that is common with topiramate, which is particularly relevant for patients who are already concerned about cognitive health or who are managing early-stage dementia alongside migraine. On the other hand, CGRP has roles throughout the body beyond migraine — it is involved in cardiovascular regulation, wound healing, and gastrointestinal function. Blocking this pathway is not without consequences, and longer-term data on what years of CGRP suppression means for overall health is still accumulating. However, if you are someone with cardiovascular risk factors, this is an area to discuss carefully with your doctor. CGRP is a potent vasodilator, and there have been theoretical concerns about blocking it in patients with established cardiovascular disease, though clinical trials did not show increased cardiac events. Patients with a history of heart attack, stroke, or severe hypertension were generally excluded from the pivotal trials, so the safety profile in those populations is less well-established.
What Side Effects Do Patients Most Commonly Report With Aimovig?
The most frequently reported side effect in both clinical trials and real-world use is constipation, which ranges from mildly annoying to severe enough that some patients discontinue treatment. In trial data, constipation occurred more frequently at the higher 140 mg dose than the 70 mg dose. Patients in online forums often describe this side effect developing gradually over the first few months and sometimes worsening with continued use. For older adults or those taking other medications that also cause constipation — including certain dementia medications — this can become a significant quality-of-life issue that needs active management with dietary changes, hydration, or stool softeners. Injection site reactions are another common report, though most patients describe these as minor — brief stinging, redness, or a small bump that resolves within a day.
The autoinjector delivery system is generally well-tolerated, though some patients find the injection uncomfortable, particularly in colder months when they have not allowed the pen to reach room temperature before use. Muscle spasms and cramps have also been reported by some patients, though these were not prominently flagged in early trial data and seem to appear more in post-marketing reports. A more concerning pattern that some patients describe involves worsening of migraines after initially responding well, sometimes after six months to a year of use. It is unclear whether this represents a true wearing-off effect, the natural fluctuation of migraine disease, or some form of adaptation. Some neurologists have tried switching patients to a different CGRP-targeting therapy in these cases with renewed benefit, suggesting the issue may be specific to the receptor-blocking approach of erenumab versus the ligand-targeting approach of drugs like fremanezumab or galcanezumab.
How Does Aimovig Compare to Other CGRP Treatments for Migraines?
Since Aimovig’s approval, several other CGRP-pathway medications have reached the market, including Ajovy (fremanezumab), Emgality (galcanezumab), and Vyepti (eptinezumab, given by IV infusion). Head-to-head comparison data between these drugs is limited, and most neurologists regard them as roughly comparable in overall efficacy for the average patient. The choice often comes down to practical factors: injection frequency (monthly versus quarterly), delivery method (autoinjector versus prefilled syringe versus infusion), insurance coverage and copay, and individual side effect tolerance. One meaningful distinction is that Aimovig blocks the CGRP receptor, while Ajovy and Emgality block the CGRP molecule itself. This is not just a pharmacological footnote — it may matter clinically.
Some patients who do not respond to one mechanism appear to respond to the other, which is why many headache specialists will try a second CGRP therapy before abandoning the class entirely. Vyepti, administered as a quarterly IV infusion in a clinical setting, removes the self-injection variable entirely, which can be an advantage for patients who struggle with adherence or have anxiety about self-injecting. The tradeoff with Aimovig specifically is that it was first to market and therefore has the longest real-world safety track record among the injectable CGRP therapies. For patients and caregivers who value that longer history of use, particularly in the context of managing complex health situations that include cognitive decline, that additional data may offer some reassurance. However, the constipation side effect appears to be somewhat more prominent with Aimovig than with the ligand-targeting alternatives, which is a relevant factor for older adults.
What Are the Cost and Access Barriers for Aimovig Injections?
Cost has been one of the most significant barriers to Aimovig access since its launch. The list price has historically been in the range of several hundred dollars per month, and while the manufacturer and various copay assistance programs have at times reduced out-of-pocket costs for commercially insured patients, those on Medicare or Medicaid have often faced much higher burdens. Insurance coverage frequently requires step therapy — meaning patients must first try and fail cheaper preventive medications before gaining approval for a CGRP therapy. This process can take months and add frustration for patients who are suffering. Pricing and assistance programs change frequently, so any specific figures cited here should be verified against current information.
What has remained fairly consistent is that access is easier for patients with commercial insurance than for those on government plans, and that prior authorization requirements vary significantly between insurers. Some patients report smooth approval processes while others describe lengthy appeals. For caregivers managing a loved one’s healthcare — particularly in dementia care settings where the patient may not be able to advocate for themselves — navigating these insurance hurdles adds a meaningful logistical burden. A practical warning: if a patient stops Aimovig for a period due to cost or access issues and then restarts, they may need to go through the titration and waiting period again. The medication does not appear to cause rebound headaches the way some acute treatments do, but the protective effect wears off after the drug clears the system, which takes several months given its long half-life. Planning ahead for potential coverage gaps is worth discussing with your prescribing physician.
What Should Dementia Caregivers Know About Aimovig and Brain Health?
Migraine disease and dementia can coexist, and the relationship between the two is an area of active research. Some epidemiological studies have suggested that people with a history of migraine, particularly migraine with aura, may have a modestly elevated long-term risk for certain types of dementia, though causation has not been established. For caregivers supporting someone who has both conditions, the question of whether treating migraines aggressively might have any protective cognitive benefit remains unanswered but is worth raising with a neurologist.
From a practical standpoint, Aimovig has an advantage over older preventives in that it does not appear to cause cognitive side effects. Topiramate, one of the most commonly prescribed migraine preventives, is notorious for causing word-finding difficulties and mental slowing — side effects that would be particularly unwelcome in someone already experiencing cognitive decline. The relatively clean cognitive profile of CGRP therapies makes them an appealing option in this population, though formal studies in patients with concurrent dementia are essentially nonexistent, and clinicians are largely relying on extrapolation from the general migraine population.
Where Is Aimovig Headed and What Are Patients Watching For?
The CGRP therapy landscape continues to evolve. Oral CGRP receptor antagonists — the gepants, including atogepant and rimegepant — have expanded options for patients who prefer pills over injections. Some of these are approved for both acute treatment and prevention, offering flexibility.
As more options enter the market, competition may eventually affect pricing and access, which would benefit patients across all insurance types. Longer-term safety data for Aimovig is also accumulating, and as of recent reports, no major unexpected safety signals have emerged beyond what was identified in clinical trials and early post-marketing surveillance. For the migraine community and for caregivers managing overlapping neurological conditions, the growing body of real-world evidence across millions of patient-months of exposure provides an increasingly complete picture of what to expect from this class of therapies.
Conclusion
Aimovig represented a genuine shift in migraine treatment when it arrived as the first CGRP-targeted therapy, and real patient experiences have largely confirmed that it works well for some people and not others — a reality that applies to virtually every migraine preventive but is important to state plainly. The patients who benefit most tend to be those with frequent migraines who have not responded adequately to older, cheaper medications, and who can tolerate the constipation and other side effects that sometimes accompany treatment.
For people navigating both migraine disease and cognitive health concerns, the absence of cognitive side effects is a meaningful advantage. If you or someone you care for is considering Aimovig, the most productive conversation to have with a neurologist involves setting realistic expectations about the timeline for response, understanding the insurance requirements that may need to be satisfied first, and having a plan for evaluating whether the medication is working after an adequate trial of three to six months. Do not hesitate to ask about alternative CGRP therapies if Aimovig does not provide sufficient relief — the class is broad enough now that one option’s failure does not mean the entire pathway is a dead end.
Frequently Asked Questions
How long does it take for Aimovig to start working?
Most neurologists recommend giving Aimovig at least three months, and ideally up to six months, before concluding it is not effective. Some patients notice improvement after the first injection, but this is not universal, and early non-response does not necessarily predict long-term failure.
Can Aimovig be used alongside other migraine medications?
Yes. Aimovig is a preventive therapy and can generally be used alongside acute treatments like triptans or gepants. Some patients also use it in combination with other preventives, though this should be managed by a headache specialist.
Is Aimovig safe for older adults with other health conditions?
Aimovig was not extensively studied in elderly populations or in patients with significant cardiovascular disease. While no major safety concerns have emerged for otherwise healthy older adults, patients with heart disease, uncontrolled hypertension, or other serious conditions should discuss risks carefully with their doctor.
What happens if I stop taking Aimovig?
The medication does not cause withdrawal or rebound headaches. However, its preventive effect gradually wears off over the weeks following the last injection as the drug clears the body. Migraine frequency typically returns to baseline levels.
Does Aimovig affect memory or thinking?
Unlike some older migraine preventives such as topiramate, Aimovig has not been associated with cognitive side effects in clinical trials or widespread patient reports. This is one reason it may be preferred for patients with existing cognitive concerns.
